|
Re: 250 MACE scenario question
|
3
|
Resverlogix Corp.
|
Jan 23, 2019 07:59PM
|
|
Re: 250 MACE scenario question
|
6
|
Resverlogix Corp.
|
Jan 24, 2019 07:44PM
|
|
Re: 250 MACE scenario question
|
4
|
Resverlogix Corp.
|
Jan 24, 2019 09:31PM
|
|
Re: 3 ASN Kidney Conference Presentations Nov 8-9
|
6
|
Resverlogix Corp.
|
Nov 08, 2019 06:56PM
|
|
Re: 3 ASN Kidney Conference Presentations Nov 8-9
|
6
|
Resverlogix Corp.
|
Nov 09, 2019 04:54PM
|
|
Re: 3 ASN Kidney Conference Presentations Nov 8-9
|
4
|
Resverlogix Corp.
|
Nov 08, 2019 08:29AM
|
|
Re: 3 ASN Kidney Conference Presentations Nov 8-9
|
3
|
Resverlogix Corp.
|
Nov 08, 2019 03:11PM
|
|
Re: 3 point MACE in Phase 3 should be 10% percent lower than 4 point MACE in Phase 2's
|
3
|
Resverlogix Corp.
|
Nov 06, 2018 11:09AM
|
|
Re: 3 point MACE in Phase 3 should be 10% percent lower than 4 point MACE in Phase 2's
|
3
|
Resverlogix Corp.
|
Nov 06, 2018 11:19AM
|
|
Re: 3 point MACE vs 5 point MACE
|
6
|
Resverlogix Corp.
|
Nov 02, 2018 10:41AM
|
|
Re: 3 point MACE vs 5 point MACE
|
5
|
Resverlogix Corp.
|
Nov 02, 2018 01:17PM
|
|
Re: 3 point MACE vs 5 point MACE
|
4
|
Resverlogix Corp.
|
Nov 02, 2018 01:23PM
|
|
Re: 3 point MACE vs 5 point MACE
|
3
|
Resverlogix Corp.
|
Nov 02, 2018 01:32PM
|
|
Re: 3 point MACE vs 5 point MACE
|
2
|
Resverlogix Corp.
|
Nov 02, 2018 02:54PM
|
|
Re: 3 point MACE vs 5 point MACE
|
7
|
Resverlogix Corp.
|
Nov 02, 2018 05:50PM
|
|
Re: 3 point MACE vs 5 point MACE
|
4
|
Resverlogix Corp.
|
Nov 02, 2018 10:29PM
|
|
Re: 3 point MACE vs 5 point MACE
|
5
|
Resverlogix Corp.
|
Nov 02, 2018 11:48PM
|
|
Re: 3 Weeks To The 31st
|
3
|
Zenith Epigenetics
|
Mar 15, 2017 09:21AM
|
|
Re: 3 Weeks To The 31st
|
5
|
Zenith Epigenetics
|
Mar 10, 2017 11:22AM
|
|
Re: 3600 patient years
|
9
|
Resverlogix Corp.
|
Feb 16, 2018 05:00PM
|
